Pharmacy

Analyzing opioid prescription patterns of US retina specialists

Investigators looked at trends by geographic variation in practice patterns, perceptions toward opioids, and patient population

(AAO) Genentech provides update on presentations, product portfolio

Chris Brittain, MBBS, BSc, MBA, MRCOphth, vice president and global head of ophthalmology product development for Genentech, provides an overview of the company’s podium presentations from the PDS with ranibizumab to faricimab.

What keeps you up at night in ophthalmology: Part II

Pharmaceutical representatives share what keeps them up at night within the ophthalmic space.

Glaucoma 360: Drug delivery contact lens technology

July 17, 2020

ICYMI: Chris Adams, CEO of Diopter Corp, discusses the company's drug delivery contact lens technology in the pipeline that works to treat ocular surface disease, during the 2020 Glaucoma 360 meeting in San Francisco, California.

Glaucoma 360: Pharmaceuticals in the glaucoma industry

July 16, 2020

ICYMI: Ramin Valian, vice president of International Glaucoma, Reimbursement and Pipeline at Allergan, discusses glaucoma from a therapeutics/diagnostics and big data sets standpoint during the 2020 Glaucoma 360 meeting.

Bepostastine solution provides comfort, safety

February 15, 2010

Bepostastine besilate ophthalmic solution 1.5% (Bepreve, ISTA Pharmaceuticals) is safe and well-tolerated in healthy children as young as 3 years of age, according to results from a multicenter, prospective, double-masked, randomized, placebo-controlled trial.

Concomitant use of tear products with cyclosporine assessed

February 15, 2010

Blink Tears Lubricating Eye Drops improved dry eye symptoms significantly better than Systane Lubricant Eye Drops when the artificial tears were paired with topical cyclosporine ophthalmic emulsion.

Topical corticosteroid valuable option in allergic conjunctivitis care

February 15, 2010

For patients who are suffering with moderate to severe signs and symptoms of seasonal or perennial allergic conjunctivitis, loteprednol etabonate ophthalmic suspension 0.2% (Alrex, Bausch & Lomb) is a safe and well-tolerated therapeutic option that can provide rapid clinical improvement, according to new research.

Efficacy of artificial tears tested under arid conditions

February 15, 2010

An efficacy evaluation comparing two marketed artificial tears showed that a polyethylene-based product (Systane Ultra, Alcon Laboratories) resulted in statisically greater reductions in corneal and conjunctival staining than a glycerin/carboxymethylcellulose-based tear (Refresh Optive, Allergan).